Equities

Smith & Nephew PLC

SN.:LSE

Smith & Nephew PLC

Health CareMedical Equipment and Services
  • Price (GBX)995.60
  • Today's Change10.00 / 1.01%
  • Shares traded-1.00
  • 1 Year change-22.13%
  • Beta0.8854
Data delayed at least 20 minutes, as of May 03 2024 09:15 BST.
More ▼

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Smith & Nephew PLC grew revenues 6.40% from 5.22bn to 5.55bn while net income improved 17.94% from 223.00m to 263.00m.
Gross margin68.82%
Net profit margin4.74%
Operating margin7.66%
Return on assets2.64%
Return on equity5.02%
Return on investment3.29%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Smith & Nephew PLC fell by 44.00m. However, the company earned 608.00m from its operations for a Cash Flow Margin of 10.96%. In addition the company used 448.00m on investing activities and also paid 200.00m in financing cash flows.
Cash flow per share0.8648
Price/Cash flow per share11.41
Book value per share4.78
Tangible book value per share1.02
More ▼

Balance sheet in USDView more

Smith & Nephew PLC has a Debt to Total Capital ratio of 37.15%, a lower figure than the previous year's 51.57%.
Current ratio1.77
Quick ratio0.72
Total debt/total equity0.5911
Total debt/total capital0.3715
More ▼

Growth rates in USD

Year on year, growth in dividends per share fell -38.97% while earnings per share excluding extraordinary items rose 18.14%. Additionally when measured on a five year annualized basis, dividend per share growth is below the industry average relative to its peers, while earnings per share growth is in-line with the industry average.
Div yield(5 year avg)2.04%
Div growth rate (5 year)-8.12%
Payout ratio (TTM)124.33%
EPS growth(5 years)-16.83
EPS (TTM) vs
TTM 1 year ago		18.27
More ▼
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.